233 related articles for article (PubMed ID: 35688554)
1. DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
Muik A; Adams 3rd HC; Gieseke F; Altintas I; Schoedel KB; Blum JM; Sänger B; Burm SM; Stanganello E; Verzijl D; Spires VM; Vascotto F; Toker A; Quinkhardt J; Fereshteh M; Diken M; Satijn DPE; Kreiter S; Ahmadi T; Breij ECW; Türeci Ö; Sasser K; Sahin U; Jure-Kunkel M
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688554
[TBL] [Abstract][Full Text] [Related]
2. XFab-α4-1BB/CD40L fusion protein activates dendritic cells, improves expansion of antigen-specific T cells, and exhibits antitumour efficacy in multiple solid tumour models.
Wang B; Liu Y; Yuan R; Dou X; Qian N; Pan X; Xu G; Xu Q; Dong B; Yang C; Li H; Wang J; Bai G; Liu L; Gao X
Cancer Immunol Immunother; 2023 Dec; 72(12):4015-4030. PubMed ID: 37863852
[TBL] [Abstract][Full Text] [Related]
3. Correction: DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity.
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096537
[No Abstract] [Full Text] [Related]
4. Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors.
Muik A; Garralda E; Altintas I; Gieseke F; Geva R; Ben-Ami E; Maurice-Dror C; Calvo E; LoRusso PM; Alonso G; Rodriguez-Ruiz ME; Schoedel KB; Blum JM; Sänger B; Salcedo TW; Burm SM; Stanganello E; Verzijl D; Vascotto F; Sette A; Quinkhardt J; Plantinga TS; Toker A; van den Brink EN; Fereshteh M; Diken M; Satijn D; Kreiter S; Breij ECW; Bajaj G; Lagkadinou E; Sasser K; Türeci Ö; Forssmann U; Ahmadi T; Şahin U; Jure-Kunkel M; Melero I
Cancer Discov; 2022 May; 12(5):1248-1265. PubMed ID: 35176764
[TBL] [Abstract][Full Text] [Related]
5. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies.
Hägerbrand K; Varas L; Deronic A; Nyesiga B; Sundstedt A; Ljung L; Sakellariou C; Werchau D; Thagesson M; Gomez Jimenez D; Greiff L; Celander M; Smedenfors K; Rosén A; Bölükbas D; Carlsson F; Levin M; Säll A; von Schantz L; Lindstedt M; Ellmark P
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323431
[TBL] [Abstract][Full Text] [Related]
6. An Fc-inert PD-L1×4-1BB bispecific antibody mediates potent anti-tumor immunity in mice by combining checkpoint inhibition and conditional 4-1BB co-stimulation.
Muik A; Altintas I; Gieseke F; Schoedel KB; Burm SM; Toker A; Salcedo TW; Verzijl D; Eisel D; Grunwitz C; Kranz LM; Vormehr M; Satijn DPE; Diken M; Kreiter S; Sasser K; Ahmadi T; Türeci Ö; Breij ECW; Jure-Kunkel M; Sahin U
Oncoimmunology; 2022; 11(1):2030135. PubMed ID: 35186440
[TBL] [Abstract][Full Text] [Related]
7. The Bispecific Tumor Antigen-Conditional 4-1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies.
Nelson MH; Fritzell S; Miller R; Werchau D; Van Citters D; Nilsson A; Misher L; Ljung L; Bader R; Deronic A; Chunyk AG; Schultz L; Varas LA; Rose N; Håkansson M; Gross J; Furebring C; Pavlik P; Sundstedt A; Veitonmäki N; Ramos HJ; Säll A; Dahlman A; Bienvenue D; von Schantz L; McMahan CJ; Askmyr M; Hernandez-Hoyos G; Ellmark P
Mol Cancer Ther; 2023 Jan; 22(1):89-101. PubMed ID: 36343381
[TBL] [Abstract][Full Text] [Related]
8. An Fc-muted bispecific antibody targeting PD-L1 and 4-1BB induces antitumor immune activity in colorectal cancer without systemic toxicity.
Cheng LS; Zhu M; Gao Y; Liu WT; Yin W; Zhou P; Zhu Z; Niu L; Zeng X; Zhang D; Fang Q; Wang F; Zhao Q; Zhang Y; Shen G
Cell Mol Biol Lett; 2023 May; 28(1):47. PubMed ID: 37259060
[TBL] [Abstract][Full Text] [Related]
9. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors.
Luke JJ; Barlesi F; Chung K; Tolcher AW; Kelly K; Hollebecque A; Le Tourneau C; Subbiah V; Tsai F; Kao S; Cassier PA; Khasraw M; Kindler HL; Fang H; Fan F; Allaire K; Patel M; Ye S; Chao DT; Henner WR; Hayflick JS; McDevitt MA; Fong L
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608377
[TBL] [Abstract][Full Text] [Related]
11. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
[TBL] [Abstract][Full Text] [Related]
12. Generation of a safe and efficacious llama single-domain antibody fragment (vHH) targeting the membrane-proximal region of 4-1BB for engineering therapeutic bispecific antibodies for cancer.
Zhai T; Wang C; Xu Y; Huang W; Yuan Z; Wang T; Dai S; Peng S; Pang T; Jiang W; Huang Y; Zou Y; Xu Y; Sun J; Gong X; Zhang J; Tsun A; Li B; Miao X
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172514
[TBL] [Abstract][Full Text] [Related]
13. CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor-directed T-cell activation.
Gao J; Wang Z; Jiang W; Zhang Y; Meng Z; Niu Y; Sheng Z; Chen C; Liu X; Chen X; Liu C; Jia K; Zhang C; Liao H; Jung J; Sung E; Chung H; Zhang JZ; Zhu AX; Shen L
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364935
[TBL] [Abstract][Full Text] [Related]
14. A Bispecific Molecule Targeting CD40 and Tumor Antigen Mesothelin Enhances Tumor-Specific Immunity.
Ye S; Cohen D; Belmar NA; Choi D; Tan SS; Sho M; Akamatsu Y; Kim H; Iyer R; Cabel J; Lake M; Song D; Harlan J; Zhang C; Fang Y; Wahl AF; Culp P; Hollenbaugh D; Chao DT
Cancer Immunol Res; 2019 Nov; 7(11):1864-1875. PubMed ID: 31462409
[TBL] [Abstract][Full Text] [Related]
15. ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1.
Enell Smith K; Fritzell S; Nilsson A; Barchan K; Rosén A; Schultz L; Varas L; Säll A; Rose N; Håkansson M; von Schantz L; Ellmark P
Cancer Immunol Immunother; 2023 Dec; 72(12):4145-4159. PubMed ID: 37796298
[TBL] [Abstract][Full Text] [Related]
16. B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8
You G; Lee Y; Kang YW; Park HW; Park K; Kim H; Kim YM; Kim S; Kim JH; Moon D; Chung H; Son W; Jung UJ; Park E; Lee S; Son YG; Eom J; Won J; Park Y; Jung J; Lee SW
Sci Adv; 2021 Jan; 7(3):. PubMed ID: 33523913
[TBL] [Abstract][Full Text] [Related]
17. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
18. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.
Hinner MJ; Aiba RSB; Jaquin TJ; Berger S; Dürr MC; Schlosser C; Allersdorfer A; Wiedenmann A; Matschiner G; Schüler J; Moebius U; Rothe C; Matis L; Olwill SA
Clin Cancer Res; 2019 Oct; 25(19):5878-5889. PubMed ID: 31138587
[TBL] [Abstract][Full Text] [Related]
20. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
Sabel MS; Conway TF; Chen FA; Bankert RB
J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
